Boothbay Fund Management’s RAPT Therapeutics RAPT Stock Holding History

Boothbay Fund Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-79,700	Closed	-$2.7M	–	2407
2025 Q4	$2.7M	Buy	79,700 +16,000	+25%	+$497K	0.04%	476
2025 Q3	$1.64M	Buy	+63,700	New	+$834K	0.02%	642
2024 Q3	–	Sell	-6,625	Closed	-$162K	–	1873
2024 Q2	$162K	Buy	6,625 +3,737	+129%	+$173K	﹤0.01%	1317
2024 Q1	$207K	Buy	+2,888	New	+$402K	﹤0.01%	1326
2021 Q2	–	Sell	-37	Closed	-$648K	–	2068
2021 Q1	$648K	Buy	+37	New	+$6.1K	0.02%	806

Boothbay Fund Management's RAPT Position: Q1 2026 in Review

Boothbay Fund Management sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 390,747 shares — an estimated $13.2M sold.

Boothbay Fund Management first reported a position in RAPT in Q1 2024 and held it in 5 quarters. The position peaked at $13.2M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Boothbay Fund Management reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Boothbay Fund Management sold 390,747 RAPT Therapeutics shares in Q1 2026, an estimated $13.2M.
Boothbay Fund Management first reported a position in RAPT Therapeutics in Q1 2024 and held it in 5 quarters.
Boothbay Fund Management's RAPT Therapeutics position peaked at $13.2M in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.